28 February 2018 EMA/MB/102050/2018 Extraordinary Management Board meeting of 28 February 2018

Agenda for the Extraordinary Management Board meeting for the building approval process of EMA premises in Amsterdam (in-camera) Held on 28 February 2018 in Lisbon (10:30-13:00) Chair: Christa Wirthumer-Hoche Item 1.

Draft agenda

2.

Declarations of competing interests related to the current

For adoption, EMA/MB/102050/2018 Oral report

agenda 3.

Minutes of the Extraordinary Management Board meeting for the building approval process of EMA premises in

For adoption, EMA/MB/84505/2018

Amsterdam (in-camera) held on 6 February 2018 4.

Follow-up to 6 February 2018 Extraordinary Management Board meeting

For information, 1304828-173926-GMT; Ref. Ares(2018)997396 21/02/2018

5.

Notification of the European Medicines Agency's intention to move to a new building in accordance with Article 88 of the Agency's Financial Regulation

For information, EMA/MB/120553/2018 For endorsement, EMA/749315/2017 – MB Version 3 and Annexes

6.

A.O.B

* Documents marked with a star * are intended for publication on the external website. ** Documents in Additional documents for information section are not intended for discussion unless specifically requested.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Agenda - European Medicines Agency - Europa EU

Feb 28, 2018 - EMA/MB/102050/2018. Extraordinary Management Board meeting of 28 February 2018. Agenda for the Extraordinary Management Board meeting for the building approval process of EMA premises in. Amsterdam (in-camera). Held on 28 February 2018 in Lisbon (10:30-13:00). Chair: Christa Wirthumer- ...

72KB Sizes 2 Downloads 237 Views

Recommend Documents

Agenda - European Medicines Agency - Europa EU
Nov 3, 2016 - Scope: 'Optimising the development of ATMPs to meet patient needs' ... the CAT would like to discuss with company representatives in person.

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - under Article 107i of Directive 2001/83/EC, based on pharmacovigilance data. Action: For adoption of ..... manufacturing process; and 3) removal of the following missing information: special patient groups. Action: For .... analysis of

Agenda - European Medicines Agency - Europa EU
4 days ago - Meningococcal group A, C, W135 and Y conjugate vaccine - NIMENRIX (CAP) -. EMEA/H/C/002226/II/0078 . ...... Applicant: AstraZeneca AB.

Agenda - European Medicines Agency - Europa EU
Jul 31, 2017 - Human Medicines Research and Development Support Division. Agenda ... use of such prior knowledge in regulatory application dossiers, to support manufacturing and control strategies ... of accelerated access schemes.

Agenda - European Medicines Agency - Europa EU
Oct 26, 2016 - (as Web sites for social networking and microblogging) through which ... 09:10. Opening remarks. D. Haerry (PCWP)/. G. Calvo (HCPWP). 1.

Agenda - European Medicines Agency - Europa EU
Nov 27, 2017 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be